6 completed, 3 terminated, 1 withdrawn. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Terminated 3, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow QGE031: new trials by email Literature Review of QGE031 trials Research Report on QGE031
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) Ligelizumab, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 49 | 2018-08-01 | 2026-01-13 |
| A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Ligelizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 226 | 2016-05-24 | 2021-10-11 |
| Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma QGE031, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 10 | 2015-09-01 | 2017-08-11 |
| Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU QGE031, Omalizumab, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Novartis Pharmaceuticals | 382 | 2015-07-15 | 2021-01-05 |
| Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 QGE031 - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 270 | 2014-03-27 | 2017-08-11 |
| Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment QGE031, Placebo - Bullous Pemphigoid | Phase 2 | Terminated | Novartis Pharmaceuticals | 20 | 2013-01-01 | 2016-04-28 |
| Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma QGE031, Omalizumab, Placebo - Asthma | Phase 2 | Completed | Novartis Pharmaceuticals | 471 | 2012-12-01 | 2017-08-11 |
| A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma QGE031, omalizumab, placebo - Allergic Asthma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 37 | 2012-11-01 | 2016-04-20 |
| A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients QGE031, Placebo, Cyclosporine A - Atopic Dermatitis | Phase 2 | Completed | Novartis Pharmaceuticals | 22 | 2012-01-05 | 2017-02-23 |
| Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy QGE031, Placebo - Peanut Allergy | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-07-23 |
Asthma (4) · Chronic Urticaria (3) · Bronchiolitis Obliterans Syndrome (2) · Hypersensitivity (2) · Urticaria (2) · Dermatitis, Atopic (1) · Epilepsy, Idiopathic Generalized (1) · Peanut Hypersensitivity (1) · Pemphigoid, Bullous (1) · Skin Diseases (1)
Germany (8) · Canada (7) · United States (6) · France (5) · Russia (5) · Hungary (4) · Japan (4) · Taiwan (4) · United Kingdom (4) · Argentina (3) · Italy (3) · Slovakia (3) · Spain (3) · Turkey (Türkiye) (3) · Australia (2)
PMID 34773261, PMID 36440464, PMID 31577874, PMID 37492920
2014 (2), 2015 (1), 2017 (1)